All stock lists
Unlock the score
BlossomHill Therapeutics, Inc. (BLSM)
NASDAQ: BLSM · Real-Time Price · USD
Healthcare · Biotechnology
16.14+1.51 (+10.34%)
Insider Score
/ 100
BLSM Insider Score
BlossomHill Therapeutics, Inc. has a live Insider Score.
Scored on 7 qualifying trades from 6 insiders in the last 90 days.
BLSM Stock Insider Trading Activity
BLSM stock’s insider trading shows 7 purchases for an estimated $25.18M by company insiders over the last 6 months.
Not enough price history.
Insider Trading Activity (Form 4 Filings)
An insider trade occurs when an individual that has non-public information about a company buys or sells shares of that company’s stock. Examples of insiders include a company’s executive officers (CEO, CFO, COO), its board of directors, and its major shareholders. Insiders are required to submit their trading activity to the SEC through Form 4 filings.
Scored window · last 90 days7 qualifying buys6 insiders$25.18M bought— these are the numbers in the rankings table; the full history below shows every filing (buys, sells and older activity).
| Insider | Action | Shares | Avg Cost | Total | Δ Holdings | Held After | Date | Grade | Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Chen Bihua Director | Buy | 312,500 | $16.00 | $5.00M | 9.5% | 3,614,034 | Aug 10, 2026 | BCluster BuyFirst Buy | Form 4 |
| GORDON CARL L Director | Converted | 1,049,283 | — | — | 101% | 2,089,279 | Aug 10, 2026 | — | Form 4 |
| GORDON CARL L Director | Buy | 625,000 | $16.00 | $10.00M | 29.9% | 2,714,279 | Aug 10, 2026 | ACluster BuyFirst Buy | Form 4 |
| ORBIMED ADVISORS LLC Director | Converted | 1,039,996 | — | — | New | 1,039,996 | Aug 10, 2026 | — | Form 4 |
| ORBIMED ADVISORS LLC Director | Converted | 1,049,283 | — | — | 101% | 2,089,279 | Aug 10, 2026 | — | Form 4 |
| ORBIMED ADVISORS LLC Director | Buy | 625,000 | $16.00 | $10.00M | 29.9% | 2,714,279 | Aug 10, 2026 | BCluster BuyFirst Buy | Form 4 |
| GORDON CARL L Director | Converted | 1,039,996 | — | — | New | 1,039,996 | Aug 10, 2026 | — | Form 4 |
| Liptak Vincent Paul Other | Buy | 2,200 | $16.00 | $35.20K | 2.0% | 111,412 | Aug 10, 2026 | CCluster Buy | Form 4 |
| Liptak Vincent Paul Other | Converted | 22,687 | — | — | New | 22,687 | Aug 10, 2026 | — | Form 4 |
| Agrawal Sundeep Director | Converted | 578,524 | — | — | New | 578,524 | Aug 10, 2026 | — | Form 4 |
| Cui Jingrong Jean CEO | Converted | 1,600,682 | — | — | New | 1,600,682 | Aug 10, 2026 | — | Form 4 |
| Cui Jingrong Jean CEO | Converted | 113,435 | — | — | 7.1% | 1,714,117 | Aug 10, 2026 | — | Form 4 |
| Cui Jingrong Jean CEO | Converted | 124,779 | — | — | New | 124,779 | Aug 10, 2026 | — | Form 4 |
| Li Yishan Director | Converted | 1,600,682 | — | — | New | 1,600,682 | Aug 10, 2026 | — | Form 4 |
| Li Yishan Director | Converted | 113,435 | — | — | 7.1% | 1,714,117 | Aug 10, 2026 | — | Form 4 |
| Li Yishan Director | Converted | 124,779 | — | — | New | 124,779 | Aug 10, 2026 | — | Form 4 |
| Keyes Jason A CFO | Buy | 700 | $16.00 | $11.20K | New | 700 | Aug 10, 2026 | ACluster BuyFirst Buy | Form 4 |
| Schmid John P. Director | Buy | 6,000 | $16.00 | $96.00K | New | 6,000 | Aug 10, 2026 | BCluster BuyFirst Buy | Form 4 |
| Chen Bihua Director | Converted | 1,599,993 | — | — | New | 1,599,993 | Aug 10, 2026 | — | Form 4 |
| Chen Bihua Director | Converted | 1,701,541 | — | — | 106% | 3,301,534 | Aug 10, 2026 | — | Form 4 |
| Liptak Vincent Paul Other | Buy | 2,500 | $15.80 | $39.50K | 2.3% | 109,212 | Aug 7, 2026 | CCluster BuyFirst Buy | Form 4 |
What these mean— the action is the SEC’s own Form 4 transaction code. Only a buy or a sell is an open-market trade; the rest are transfers, awards and exercises, which is why they carry no price.
- Buy (P) — Open-market or private purchase
- Converted (C) — Conversion of a derivative security into shares
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.